A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia | MicrobiomeTrials← Back to trialsNCT05600920
A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2024-11-06Est. Completion: 2026-11-01
Enrollment target: 60 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Idiopathic CD4-PositiveT-Lymphocytopenia
Idiopathic CD4 lymphocytopenia (ICL) is a rare syndrome defined by consistently low CD4 T cell counts (\<300/mm3) withou…
Bethesda, United StatesEst. completion Oct 31, 2026
Idiopathic CD4+ LymphocytopeniaCryptococcal MeningitisWarts
Background:
* Idiopathic CD4+ lymphocytopenia (ICL) is a condition in which there is a decreased level of CD4+ lymphocy…
Bethesda, United States